TY - JOUR
T1 - Analysis of BRCA1 and RAD51C promoter methylation in italian families at high-risk of breast and ovarian cancer
AU - Tabano, Silvia
AU - Azzollini, Jacopo
AU - Pesenti, Chiara
AU - Lovati, Sara
AU - Costanza, Jole
AU - Fontana, Laura
AU - Peissel, Bernard
AU - Miozzo, Monica
AU - Manoukian, Siranoush
PY - 2020/4
Y1 - 2020/4
N2 - Previous studies on breast and ovarian carcinoma (BC and OC) revealed constitutional BRCA1 and RAD51C promoter hypermethylation as epigenetic alterations leading to tumor predisposition. Nevertheless, the impact of epimutations at these genes is still debated. One hundred and eight women affected by BC, OC, or both and considered at very high risk of carrying BRCA1 germline mutations were studied. All samples were negative for pathogenic variants or variants of uncertain significance at BRCA testing. Quantitative BRCA1 and RAD51C promoter methylation analyses were performed by Epityper mass spectrometry on peripheral blood samples and results were compared with those in controls. All the 108 analyzed cases showed methylation levels at the BRCA1/RAD51C promoter comparable with controls. Mean methylation levels (± stdev) at the BRCA1 promoter were 4.3% (± 1.4%) and 4.4% (± 1.4%) in controls and patients, respectively (p > 0.05; t-test); mean methylation levels (± stdev) at the RAD51C promoter were 4.3% (± 0.9%) and 3.7% (± 0.9%) in controls and patients, respectively (p > 0.05; t-test). Based on these observations; the analysis of constitutional methylation at promoters of these genes does not seem to substantially improve the definition of cancer risks in patients. These data support the idea that epimutations represent a very rare event in high-risk BC/OC populations.
AB - Previous studies on breast and ovarian carcinoma (BC and OC) revealed constitutional BRCA1 and RAD51C promoter hypermethylation as epigenetic alterations leading to tumor predisposition. Nevertheless, the impact of epimutations at these genes is still debated. One hundred and eight women affected by BC, OC, or both and considered at very high risk of carrying BRCA1 germline mutations were studied. All samples were negative for pathogenic variants or variants of uncertain significance at BRCA testing. Quantitative BRCA1 and RAD51C promoter methylation analyses were performed by Epityper mass spectrometry on peripheral blood samples and results were compared with those in controls. All the 108 analyzed cases showed methylation levels at the BRCA1/RAD51C promoter comparable with controls. Mean methylation levels (± stdev) at the BRCA1 promoter were 4.3% (± 1.4%) and 4.4% (± 1.4%) in controls and patients, respectively (p > 0.05; t-test); mean methylation levels (± stdev) at the RAD51C promoter were 4.3% (± 0.9%) and 3.7% (± 0.9%) in controls and patients, respectively (p > 0.05; t-test). Based on these observations; the analysis of constitutional methylation at promoters of these genes does not seem to substantially improve the definition of cancer risks in patients. These data support the idea that epimutations represent a very rare event in high-risk BC/OC populations.
KW - BRCA1
KW - Breast carcinoma
KW - Germline epigenetic defects
KW - Ovarian carcinoma
KW - Promoter methylation
KW - RAD51C
UR - http://www.scopus.com/inward/record.url?scp=85083794450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083794450&partnerID=8YFLogxK
U2 - 10.3390/cancers12040910
DO - 10.3390/cancers12040910
M3 - Article
AN - SCOPUS:85083794450
VL - 12
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 4
M1 - 910
ER -